Moreover, ADAM10 sheddase activity was reported to be notably higher in aggressive NSCLC tumours and in exosomes from the blood of NSCLC patients, suggesting its potential as a significant biomarker, despite inconsistent protein expression levels in primary tumours [96]. This evidence concerns the gene ADAM10 and neoplasm.